Every 8-K that SpyGlass Pharma, Inc. (SGP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SGP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGP filings page.
SpyGlass Pharma (SGP) completed its acquisition of 100% of Advanced Vision Science, Inc. (AVS) on October 1, 2026. The purchase price was estimated at $13 million and is subject to customary post-Closing adjustment; the company described the consideration as approximately $13 million in cash.
AVS was SpyGlass Pharma’s intraocular lens supplier and currently supplies lenses for the BIM-IOL System in two Phase 3 registrational trials. Under a new supply and distribution agreement, AVS will continue manufacturing and supplying IOL products under the Eternity brand to Santen Pharmaceutical Co., Ltd.; Santen received the exclusive right to sell those products in Japan.
AVS and Santen also entered into reciprocal intellectual-property licenses: AVS granted Santen a non-exclusive, non-sublicensable license to certain AVS intellectual property, while Santen granted AVS a non-exclusive license to certain Santen intellectual property. SpyGlass Pharma said the acquisition secures commercial IOL manufacturing capacity and advances its pathway to adding premium lens options to the BIM-IOL System. AVS will continue licensing its hydrophobic acrylic lens material to Bausch + Lomb and manufacturing products for other global IOL companies.
SpyGlass Pharma reported second‑quarter 2026 results and pipeline updates centered on its glaucoma programs. Parallel Phase 3 registrational trials of the BIM‑IOL System remain on track, with enrollment completion expected in 2027, while a first‑in‑human trial of the BIM‑DRS is expected to begin in the second half of 2026.
Cash, cash equivalents and short‑term investments were $234.2 million as of June 30, 2026, which the company expects will fund planned operations through 2028. Research and development expense was $10.9 million and general and administrative expense was $11.0 million for the quarter, leading to a net loss of $19.9 million, or ($0.59) per share. Total assets were $243.4 million and stockholders’ equity was $232.4 million at quarter‑end. SpyGlass also highlighted approval of a dedicated Category III CPT add‑on code for the BIM‑IOL System and recent strengthening of its commercial leadership ahead of potential future commercialization.
SpyGlass Pharma reported first quarter 2026 results and clinical progress for its glaucoma programs. The company ended March 31, 2026 with cash, cash equivalents and short‑term investments of $251.0 million, which it expects will fund planned operations through 2028, supported by its February IPO that raised about $172.5 million in gross proceeds.
Topline 12‑month Phase 1/2 data for the BIM‑IOL System at the intended commercial 78‑mcg dose showed a 34% mean intraocular pressure reduction, with 98% of evaluable patients free from all topical IOP‑lowering medications and vision outcomes comparable to state‑of‑the‑art intraocular lenses. Two registrational Phase 3 BIM‑IOL trials have started surgeries and are expected to complete enrollment in 2027, while a first‑in‑human trial for the BIM‑DRS ring system is planned for the second half of 2026.
For the quarter, research and development expenses were $8.5 million and general and administrative expenses were $6.9 million. Net loss was $13.8 million, or ($0.69) per share, compared with a net loss of $8.8 million, or ($3.96) per share, in the same period of 2025.
SpyGlass Pharma reported a 2025 net loss of $39.9 million, reflecting higher research and development and administrative spending as it advanced late-stage eye therapies. Cash, cash equivalents and short-term investments were $107.4 million as of December 31, 2025, before IPO proceeds.
The company completed an initial public offering in February 2026, raising about $172.5 million and expects its cash to fund planned operations through 2028. Positive 12‑month Phase 1/2 data for the BIM‑IOL System showed 34–42% reductions in intraocular pressure and near-universal freedom from eye drops, with visual acuity around 20/20.
Two registrational Phase 3 BIM‑IOL trials in glaucoma and ocular hypertension are underway, with full enrollment expected in 2027. SpyGlass also plans a first‑in‑human BIM‑DRS trial in the second half of 2026 and four‑year BIM‑IOL first‑in‑human follow‑up data in the fourth quarter of 2026.
SpyGlass Pharma, Inc. reported positive 12‑month Phase 1/2 results for its Bimatoprost Drug Pad‑IOL System (BIM‑IOL System) in patients with open‑angle glaucoma or ocular hypertension undergoing cataract surgery.
In 104 randomized patients, evaluable participants in the 78‑mcg and 39‑mcg BIM‑IOL dose groups achieved a 34% and 42% reduction in mean intraocular pressure (IOP) from baseline at 8 a.m., compared with a 35% reduction in the control group using timolol drops. At 12 months, 98% of evaluable patients in the 78‑mcg group and 96% in the 39‑mcg group were free from all topical IOP‑lowering medications.
Vision outcomes were strong, with all evaluable BIM‑IOL patients reaching 20/32 or better best corrected distance visual acuity and a mean equivalent to 20/20 vision, and overall safety was comparable to routine cataract surgery with no serious ocular adverse events. SpyGlass is continuing long‑term follow‑up and has begun two registrational Phase 3 trials of the 78‑mcg dose, with plans to work with the FDA toward a 505(b)(2) New Drug Application.
SpyGlass Pharma, Inc. updated its executive pay disclosure after finalizing 2025 performance bonuses. The Compensation Committee approved performance cash bonuses for the company’s named executive officers for the year ended December 31, 2025, and these amounts are now reflected in an updated summary compensation table.
For 2025, CEO Patrick Mooney’s total compensation is shown as $3,322,711, including $215,088 in non‑equity incentive plan compensation. President, Chief Medical Officer and Executive Chair Malik Y. Kahook, M.D. is reported with total 2025 compensation of $2,484,469, including a $125,975 performance bonus. Chief Research & Development Officer Chetan Pujara, Ph.D., who began employment in February 2025, is listed with total 2025 compensation of $1,539,952, including a $126,289 performance bonus.
SpyGlass Pharma completed its initial public offering, selling 10,781,250 shares of common stock, including 1,406,250 from the full exercise of the underwriters’ option, at $16.00 per share for aggregate gross proceeds of $172.5 million. All shares were offered by the company, and its stock now trades on the Nasdaq Global Select Market under the symbol SGP.
The company appointed industry executive Habib Dable as a Class I director and compensation committee member, granted him an option to purchase 27,400 shares vesting monthly over 36 months, and outlined ongoing annual option grants of 13,700 shares. In connection with the IPO’s completion, SpyGlass adopted an amended and restated certificate of incorporation and bylaws, which define key governance and capital structure terms.